Please use this identifier to cite or link to this item:
Title: Early Sedation with Dexmedetomidine in Critically Ill Patients.
Austin Authors: Shehabi, Yahya;Howe, Belinda D;Bellomo, Rinaldo ;Arabi, Yaseen M;Bailey, Michael;Bass, Frances E;Bin Kadiman, Suhaini;McArthur, Colin J;Murray, Lynnette;Reade, Michael C;Seppelt, Ian M;Takala, Jukka;Wise, Matt P;Webb, Steven A
Affiliation: Adult Critical Care, University Hospital of Wales, Cardiff, United Kingdom
Department of Anesthesiology and Intensive Care, IJN-UTM Cardiovascular Engineering Center, National Heart Institute, Kuala Lumpur, Malaysia
Department of Critical Care Medicine, Auckland City Hospital, University of Auckland, Auckland, New Zealand
Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
School of Clinical Sciences, Monash University, Melbourne, VIC, Australia
Sydney Medical School-Nepean, University of Sydney, Sydney, NSW, Australia
the Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia
Department of Clinical Medicine, Macquarie University, Sydney, NSW, Australia
Monash Health, Melbourne, VIC, Australia
Faculty of Medicine, University of Queensland, Royal Brisbane and Women's Hospital, Brisbane, Australia
Faculty of Medicine, University of Melbourne, Melbourne, VIC, Australia
Joint Health Command, Australian Defence Force, Canberra, ACT, Australia
Austin Health, Heidelberg, Victoria, Australia
St. John of God Subiaco Hospital, Subiaco, WA, Australia
Prince of Wales Clinical School of Medicine, University of New South Wales Sydney, NSW, Australia
Royal North Shore Hospital, the George Institute for Global Health Sydney, NSW, Australia
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, King Abdulaziz Medical City, Riyadh, Saudi Arabia
Issue Date: 2019 2019-05-19
Publication information: The New England Journal of Medicine 2019; 380(26): 2506-2517
Abstract: Dexmedetomidine produces sedation while maintaining a degree of arousability and may reduce the duration of mechanical ventilation and delirium among patients in the intensive care unit (ICU). The use of dexmedetomidine as the sole or primary sedative agent in patients undergoing mechanical ventilation has not been extensively studied. In an open-label, randomized trial, we enrolled critically ill adults who had been undergoing ventilation for less than 12 hours in the ICU and were expected to continue to receive ventilatory support for longer than the next calendar day to receive dexmedetomidine as the sole or primary sedative or to receive usual care (propofol, midazolam, or other sedatives). The target range of sedation-scores on the Richmond Agitation and Sedation Scale (which is scored from -5 [unresponsive] to +4 [combative]) was -2 to +1 (lightly sedated to restless). The primary outcome was the rate of death from any cause at 90 days. We enrolled 4000 patients at a median interval of 4.6 hours between eligibility and randomization. In a modified intention-to-treat analysis involving 3904 patients, the primary outcome event occurred in 566 of 1948 (29.1%) in the dexmedetomidine group and in 569 of 1956 (29.1%) in the usual-care group (adjusted risk difference, 0.0 percentage points; 95% confidence interval, -2.9 to 2.8). An ancillary finding was that to achieve the prescribed level of sedation, patients in the dexmedetomidine group received supplemental propofol (64% of patients), midazolam (3%), or both (7%) during the first 2 days after randomization; in the usual-care group, these drugs were administered as primary sedatives in 60%, 12%, and 20% of the patients, respectively. Bradycardia and hypotension were more common in the dexmedetomidine group. Among patients undergoing mechanical ventilation in the ICU, those who received early dexmedetomidine for sedation had a rate of death at 90 days similar to that in the usual-care group and required supplemental sedatives to achieve the prescribed level of sedation. More adverse events were reported in the dexmedetomidine group than in the usual-care group. (Funded by the National Health and Medical Research Council of Australia and others; SPICE III number, NCT01728558.).
DOI: 10.1056/NEJMoa1904710
ORCID: 0000-0003-4707-7462
PubMed URL: 31112380
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 30, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.